NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 3 நாட்களுக்கு முன்இன்று 57 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Jyothy Labs Hikes Buyback Price to ₹240/share, Trims Offer Size to 61.25 Lakh Shares
Jyothy Labs has released an addendum to its public announcement regarding its tender offer share buyback. The company has revised the buyback price upward from ₹215 to ₹240 per equity share, representing an 18.4% premium over the current market price of ₹202.7. Consequently, the maximum number of shares to be repurchased has been reduced from 68,37,210 to 61,25,000 equity shares, which represents up to 1.67% of total paid-up equity shares. The total outlay remains capped at approximately ₹147 crore.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe buyback price was raised by ₹25 per share to ₹240, while the aggregate shares to be repurchased decreased by 7,12,210 shares to keep total consideration constant.
ஏன் இது முக்கியம்The higher offer price provides a better exit/tender premium for participating shareholders, though it repurchases a slightly smaller portion of outstanding equity capital (1.67%).
Revised buyback price: ₹ 240 /-Previous buyback price: ₹ 215/-Revised maximum shares: 61,25,000Percentage of equity capital: 1.67%Estimated buyback outlay vs Net Worth: ~9.7%
📅 குறுகிய காலம்The higher offer price provides near-term downside support to the stock price toward the ₹240 tender mark.
📈 நீண்ட காலம்Limited long-term structural impact as the buyback extinguishes only 1.67% of equity share capital.
⚠ அபாய எச்சரிக்கைகள்
Tender offer acceptance ratio risk depending on overall participation
👀 கவனிக்க வேண்டியவை
Track the upcoming schedule of the tender offer, including the record date and tendering period dates, to calculate retail entitlement ratios.
Jyothy Labs Q2 Concall: EBITDA Margin Drops to 2.5%, Revenue at ₹760 Cr Amid Severe Cost Headwinds
Jyothy Labs released its Q2 earnings conference call transcript, highlighting significant margin compression due to crude derivative and packaging cost inflation. Q2 revenue rose 3.3% YoY to ₹760 crore, while operating EBITDA margin contracted sharply to 2.5% (EBITDA of ₹19 crore) from 16.1% in the prior year, bringing PAT down to ₹10.6 crore. Excluding the discontinued Pril and Fa license business, underlying value growth was 12.4% and volume growth was 8.1%. Management noted gross margins fell to 34.8% (vs 48.1% YoY) as input costs surged, and stated that margin recovery would be gradual through selective price hikes.
உச்சம் நம்பிக்கை
என்ன மாறியதுFiling of the official transcript of the Q2 earnings conference call held on November 4, 2026.
ஏன் இது முக்கியம்Provides detailed management commentary explaining the sharp drop in operating profitability to 2.5% and outlining margin restoration plans.
📅 குறுகிய காலம்Profitability remains severely depressed due to input cost pressures; near-term focus will be on the efficacy of calibrated price hikes and packaging cost adjustments.
📈 நீண்ட காலம்Long-term recovery hinges on shifting the portfolio mix toward non-crude-dependent categories, scaling liquid detergents, and executing new product launches.
⚠ அபாய எச்சரிக்கைகள்
High raw material concentration with crude-linked inputs accounting for 60-65% of consumption
Loss of revenue contribution following the expiration of Pril and Fa brand licenses in May 2026
Inability to fully pass on input inflation without hurting volume growth
👀 கவனிக்க வேண்டியவை
Track subsequent quarters for gross margin recovery, pricing/grammage adjustments, and crude derivative cost stabilization.
Jyothy Labs Announces ₹147 Cr Share Buyback at ₹215 per Share via Tender Offer
Jyothy Labs has released its public announcement for a share buyback of up to 68,37,210 equity shares at ₹215 per share via the tender offer route. The total buyback size is up to ₹147.00 crore, which represents approximately 2.0% of the company's current market cap of ₹7,290 crore and 9.7% of its net worth. The offer price of ₹215 reflects an 8.2% premium over the current market price of ₹198.70. The board resolutions approving the operational execution and appointment of intermediaries have been formally submitted.
உச்சம் நம்பிக்கை
என்ன மாறியதுJyothy Labs submitted the formal public announcement and certified board resolutions detailing the parameters of its ₹147 crore share buyback.
ஏன் இது முக்கியம்The buyback deploys surplus cash to return capital to shareholders at an 8.2% premium to market price, which will slightly reduce the share count and improve EPS.
Buyback price: ₹215 per shareBuyback size: ₹147,00,00,150Shares to be bought back: 68,37,210Buyback size vs Market cap: ~2.0%Buyback size vs Net worth: ~9.7%
📅 குறுகிய காலம்The ₹215 tender price offers short-term price support near current levels (₹198.70), with retail activity expected around the record date announcement.
📈 நீண்ட காலம்Limited; repurchasing ~1.86% of total equity will marginally expand EPS and ROCE, but overall structural growth remains dependent on FMCG volume recovery.
⚠ அபாய எச்சரிக்கைகள்
Low acceptance ratio if tender participation from institutional and retail shareholders is high
👀 கவனிக்க வேண்டியவை
Track the upcoming announcement of the record date and tendering schedule to evaluate retail entitlement and acceptance ratios.
Jyothy Labs Approves ₹147 Cr Buyback at ₹215/Share; Record Date Nov 11, 2026
Jyothy Labs has approved a share buyback of up to 68,37,210 equity shares (1.86% of total equity) via the tender offer route at ₹215 per share, representing an aggregate size of up to ₹147 Cr. The buyback price of ₹215 is at a ~16.9% premium to the current market price of ₹183.9. Promoters, who hold 62.88% of the company, have stated they will not participate in the buyback, effectively increasing non-promoter acceptance ratios. The record date to determine eligible shareholders is fixed for November 11, 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுBoard approved a ₹147 Cr tender-route buyback at ₹215/share and set November 11, 2026 as the record date.
ஏன் இது முக்கியம்The buyback represents 9.70% of net worth and free reserves, returning capital to public shareholders with zero promoter participation, which will marginally expand promoter holding post-buyback.
Buyback price: ₹215 per Equity ShareBuyback size: ₹147,00,00,150Shares to be bought back: 68,37,210Equity capital bought back: 1.86%Buyback size vs Net Worth: ~9.25%ரெக்கார்ட் தேதி: 11-நவ.-2026
📅 குறுகிய காலம்Supportive of the stock in the near term given the ~17% premium to current market price and higher effective acceptance ratio for public holders due to promoter non-participation.
📈 நீண்ட காலம்Limited; capital return represents under 2% of equity base, though it demonstrates disciplined cash utilization given company's low leverage (D/E of 0.03).
⚠ அபாய எச்சரிக்கைகள்
Tender route acceptance ratio depends heavily on small shareholder participation levels.
👀 கவனிக்க வேண்டியவை
Track the upcoming Letter of Offer for retail shareholder entitlement ratios and the opening/closing dates of the tender window.
Jyothy Labs Q2 FY27 Results: PAT Drops to ₹10.6 Cr, EBITDA Margin Contracts to 2.5%
Jyothy Labs reported its Q2 FY27 financial results, posting revenue from operations of ₹760 crore, a modest reported value growth of 3.3% YoY. Severe input cost inflation in palm oil, crude derivatives, chemicals, and packaging squeezed operating profitability sharply, sending Operating EBITDA down to ₹19.2 crore with an EBITDA margin of just 2.5% (down from usual ~16% levels). Profit After Tax fell substantially to ₹10.6 crore for the quarter. Excluding the Pril and Fa businesses, core portfolio revenue increased by 12.4% in value and 8.1% in volume.
உச்சம் நம்பிக்கை
என்ன மாறியதுJyothy Labs disclosed its Q2 and H1 FY27 results showing steep margin contraction driven by commodity cost pressures despite stable core volume growth.
ஏன் இது முக்கியம்Operating EBITDA margins dropped to 2.5% compared to historical levels of ~16-17%, severely impacting quarterly bottom-line profitability.
📅 குறுகிய காலம்Market sentiment is likely to remain weak given the steep earnings decline and margin compression in Q2 FY27.
📈 நீண்ட காலம்Sustained volume growth in the core Fabric and Home Care categories provides underlying stability, but structural margin restoration depends on commodity price moderation and pricing power.
⚠ அபாய எச்சரிக்கைகள்
Severe input cost inflation (palm oil, crude derivatives, chemicals)
Margin compression to low single digits (2.5% EBITDA margin)
Limited near-term pricing power amidst FMCG competition
👀 கவனிக்க வேண்டியவை
Watch for management's pricing actions and raw material cost trajectories in the upcoming quarters to see how quickly operating margins can recover toward historical ranges (~16%).
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Q1 FY27 Call Transcript: EBITDA Margin Falls 820 bps to 8.4% on Raw Material Inflation
Jyothy Labs released the transcript of its Q1 FY27 earnings call, highlighting significant near-term margin pressure caused by crude-linked input cost inflation. Excluding the discontinued Pril business, revenue grew 8.1% in value and 5.3% in volume YoY, led by Fabric Care (+14% value, +10% volume). However, gross margin contracted 950 bps YoY to 38.5% and EBITDA margin dropped 820 bps YoY to 8.4% despite cutting A&P spending from 10.8% to 6.5% of revenue. Management expects H2 FY27 margins to improve progressively and reported a healthy net cash balance of approximately ₹850 crore.
உச்சம் நம்பிக்கை
என்ன மாறியதுFiling of the official Q1 FY27 earnings conference call transcript, detailing segment reclassification (Fabric Care, Home Care, Personal Care) and the impact of the Pril divestment effective May 31, 2026.
ஏன் இது முக்கியம்High raw material inflation in crude-linked inputs severely compressed operating profitability (EBITDA margin halved to 8.4%), showing temporary limits to pricing power in core categories amid intense competition.
📅 குறுகிய காலம்Margin recovery will be delayed as high-cost raw material inventory continues to flow through Q2 FY27, with relief expected only from Q3 (October onwards).
📈 நீண்ட காலம்Volume growth in Fabric Care remains robust (10%), and the ₹850 crore cash balance provides a strong buffer while the company scales higher-margin Personal Care and new launches.
⚠ அபாய எச்சரிக்கைகள்
Crude and commodity inflation squeezing gross margins
50.8% PAT Drop in Q1 FY27 as Gross Margins Contract to 38.5%
Jyothy Labs reported a weak Q1 FY27 with PAT declining 50.8% YoY to ₹47.6 Cr, primarily driven by a sharp contraction in gross margins from 48% to 38.5%. While headline revenue grew 3% to ₹773 Cr, underlying growth (excluding divested brands Pril & Fa) was healthier at 8.1% value and 5.3% volume. Operating EBITDA fell 47.9% to ₹64.7 Cr as raw material inflation and packaging costs pressured the bottom line. The company has restructured its reporting into three segments: Fabric Care, Home Care, and Personal Care.
உச்சம் நம்பிக்கை
என்ன மாறியதுA significant deterioration in profitability despite stable volume growth, alongside a restructuring of business segments into three core pillars.
ஏன் இது முக்கியம்The sharp margin drop indicates high sensitivity to input costs and limited immediate pricing power in a competitive FMCG environment, significantly impacting short-term earnings quality.
📅 குறுகிய காலம்Negative sentiment is expected due to the nearly 50% drop in EBITDA and PAT, reflecting severe margin pressure that may persist until input costs stabilize.
📈 நீண்ட காலம்The company is focusing on volume-led growth and expanding into new formats like liquids and incense sticks, but structural margin recovery is the key long-term monitorable.
⚠ அபாய எச்சரிக்கைகள்
Raw material inflation
Packaging cost volatility
Intense competition from MNCs
Significant margin contraction
👀 கவனிக்க வேண்டியவை
Monitor the trajectory of crude-linked raw material prices and the company's ability to pass on costs through pricing. Watch the scaling of new launches like Maxo Agarbatti and Exo Liquid to see if they can improve the margin profile in upcoming quarters.
₹773 Cr Revenue in Q1 FY27; EBITDA Margins Contract to 8.4% Amid Commodity Inflation
Jyothy Labs reported a modest 3.0% YoY revenue growth to ₹773 crore for Q1 FY27, though its core portfolio (excluding Pril and Fa) showed stronger resilience with 8.1% value growth. Profitability was significantly impacted by elevated crude-linked input costs and commodity inflation, causing Operating EBITDA margins to drop to 8.4%, well below the TTM average of 16.1%. PAT for the quarter stood at ₹47.6 crore, representing approximately 14% of the TTM PAT. While the Fabric Care segment performed well with 10.2% volume growth, urban demand remains subdued.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company faced significant commodity headwinds and a transition in its Pril/Fa portfolio, leading to a sharp decline in operating margins despite steady volume growth in its core Fabric Care business.
ஏன் இது முக்கியம்The margin contraction to 8.4% (vs 16.1% TTM) indicates that input cost pressures are currently outpacing the company's pricing power and cost-efficiency measures, posing a short-term risk to earnings growth.
Revenue (Q1 FY27): ₹773 கோடிOperating EBITDA Margin: 8.4%PAT (Q1 FY27): ₹47.6 கோடிFabric Care Volume Growth: 10.2%Q1 வருவாய் vs TTM வருவாய்: 26.7%
📅 குறுகிய காலம்The stock may face pressure in the short term due to the significant margin miss compared to historical performance and TTM averages.
📈 நீண்ட காலம்Structural growth remains tied to rural expansion and the success of new launches like Exo Dishwash Liquid and Maxo Incense Sticks; however, margin recovery is essential for long-term value creation.
⚠ அபாய எச்சரிக்கைகள்
Significant margin contraction
Crude-linked input cost volatility
Subdued urban consumption
👀 கவனிக்க வேண்டியவை
Investors should monitor the trend of crude-linked raw material prices and the company's ability to implement 'calibrated pricing actions' to recover margins. The key metric to watch in the next quarter is whether EBITDA margins stabilize back toward the 15-16% range.
₹47.64 Cr Q1 Net Profit: Jyothy Labs Profit Drops 50.8% YoY Amid Rising Material Costs
Jyothy Labs reported a modest 2.95% YoY revenue growth to ₹773.40 Cr for Q1 FY27, but net profit plummeted 50.8% to ₹47.64 Cr from ₹96.79 Cr in the year-ago period. The primary headwind was a 49.9% surge in material costs, which reached ₹530.33 Cr, significantly compressing margins. While the Fabric Care segment showed resilience with 14.1% revenue growth, the Home Care segment's profitability crashed by 82.4% YoY. Basic EPS for the quarter halved to ₹1.30 compared to ₹2.64 in Q1 FY26.
உச்சம் நம்பிக்கை
என்ன மாறியதுJyothy Labs faced a significant margin squeeze in Q1 FY27, with material costs rising much faster than revenue, leading to a sharp decline in bottom-line performance.
ஏன் இது முக்கியம்The results indicate a struggle to pass on input cost increases to consumers, particularly in the Home Care segment, which could impact the company's TTM profitability and valuation multiples.
Q1 வருவாய்: ₹773.40 கோடிQ1 Net Profit: ₹47.64 கோடிMaterial Cost YoY Increase: 49.9%Fabric Care Revenue Growth: 14.1%Home Care PBIT Decline: 82.4%Q1 வருவாய் vs TTM வருவாய்: 26.7%
📅 குறுகிய காலம்The stock is likely to face downward pressure in the short term as the market reacts to the significant profit miss and margin contraction.
📈 நீண்ட காலம்Long-term recovery depends on the stabilization of raw material prices and the company's ability to leverage its volume-led expansion strategy in rural markets to regain operating leverage.
⚠ அபாய எச்சரிக்கைகள்
Severe raw material cost inflation
Sharp margin contraction in Home Care segment
Limited pricing power in a competitive FMCG environment
👀 கவனிக்க வேண்டியவை
Investors should monitor management's commentary regarding raw material price volatility and their ability to implement price hikes to restore margins. The sharp decline in Home Care profitability is a key area of concern for the next few quarters.
Jyothy Labs 35th AGM: Rs 3.50 Dividend Declared; Pril & Fa Licenses to End May 2026
Jyothy Labs concluded its 35th AGM, confirming a final dividend of Rs 3.50 per share for FY 2025-26. A significant strategic update involves the non-renewal of Henkel's Pril and Fa brand licenses after May 31, 2026, with the company pivoting to its owned brand 'Exo' for dishwash formats. Operationally, the company added approximately 100,000 outlets and achieved 26% growth in modern trade and e-commerce channels. Sustainability efforts were highlighted with Zero Liquid Discharge implemented at 12 plants.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company officially concluded its 35th AGM, ratifying the FY26 dividend and re-appointing directors while providing a firm end-date for licensed brands.
ஏன் இது முக்கியம்Confirms the payout to shareholders and signals a strategic shift toward owned brands to replace licensed revenue streams, which may impact long-term margins.
Dividend per share: Rs 3.50Modern Trade/E-comm growth: 26%Outlets added: 1,00,000Shareholder attendance: 47.64%Plants with Zero Liquid Discharge: 12
📅 குறுகிய காலம்Neutral; the dividend payout and AGM proceedings are expected. The market will look for the record date and payment timeline.
📈 நீண்ட காலம்The shift from licensed brands (Pril/Fa) to owned brands (Exo) is a structural change that could impact margins and brand equity in the dishwash segment over the next 2-3 years.
⚠ அபாய எச்சரிக்கைகள்
Loss of licensed brands (Pril, Fa) by May 2026
Volatile input costs
Intense competition from MNCs in the personal care segment
👀 கவனிக்க வேண்டியவை
Monitor the transition of the dishwash portfolio from the licensed 'Pril' brand to the owned 'Exo' brand and its impact on market share post-May 2026.
Jyothy Labs has ceased manufacturing and distributing Henkel-owned brands 'Pril' and 'Fa' effective June 1, 2026, after Henkel declined to renew the 15-year license agreement. The 'Pril' brand is a significant contributor, accounting for approximately 7-8% of the company's total revenue (est. ₹225-240 crores). The company has initiated arbitration at the Singapore International Arbitration Center (SIAC) to dispute the exit framework and seek compensation for the goodwill created over the license period. Management expects FY 2027 to be a transition year with near-term margin softness as they pivot to scaling their in-house brand 'Exo' in the dishwash liquid segment.
முக்கிய அம்சங்கள்
Henkel terminated the brand license for Pril and Fa effective June 1, 2026, after 15 years of partnership.Pril brand accounts for approximately 7% to 8% of Jyothy Labs' total annual revenue.Company has initiated legal arbitration at SIAC regarding contractual rights and valuation of business momentum/goodwill.Management expects FY 2027 to be a transition year with anticipated pressure on revenue mix and operating margins.Perpetual licenses for Henko and Mr. White brands remain unaffected and carry no royalty obligations.
👀 கவனிக்க வேண்டியவை
Investors should brace for short-term revenue and margin volatility in FY 2027 and closely monitor the company's ability to migrate Pril's consumer base to the 'Exo' brand. The outcome of the SIAC arbitration remains a key monitorable for potential one-time cash inflows from goodwill valuation.
Jyothy Labs Announces ₹3.50 Final Dividend and 35th AGM Scheduled for July 14, 2026
Jyothy Labs Limited has convened its 35th Annual General Meeting (AGM) for July 14, 2026, to adopt the FY 2025-26 financial statements. The Board has recommended a final dividend of ₹3.50 per equity share of ₹1 face value, with the record date set for June 29, 2026. Key agenda items include the re-appointment of Mr. Aditya Sapru as an Independent Director for a second five-year term and approval for director commissions up to 1% of net profits.
முக்கிய அம்சங்கள்
Proposed final dividend of ₹3.50 per equity share for the financial year 2025-26.Record date for dividend eligibility is fixed as Monday, June 29, 2026.Re-appointment of Mr. Aditya Sapru as Independent Director for a second 5-year term from 2027 to 2032.Approval sought for annual commission to non-executive directors not exceeding 1% of net profits.The 35th AGM will be conducted virtually via Video Conferencing on July 14, 2026.
👀 கவனிக்க வேண்டியவை
Investors seeking the ₹3.50 dividend must ensure they hold the stock before the record date of June 29, 2026. Shareholders should also review the proposed remuneration and director re-appointments during the virtual AGM.
Jyothy Labs Shares Recording of Call on PRIL and Fa Brand License Updates
Jyothy Labs Limited has released the audio recording of its analyst and investor conference call held on June 18, 2026. The primary focus of the call was to provide updates regarding the licensing of the 'PRIL' and 'Fa' brands. This disclosure is in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Investors can access the recording through the link provided on the company's official website.
முக்கிய அம்சங்கள்
Conference call conducted on June 18, 2026, at 17:00 hours IST specifically for brand license updates.Discussion centered on the 'PRIL' and 'Fa' brand licenses, which are key components of the company's product portfolio.The recording has been made publicly available via a direct link on the Jyothy Labs website for transparency.The filing follows a prior intimation regarding the call sent to exchanges on June 15, 2026.
👀 கவனிக்க வேண்டியவை
Investors should listen to the recording to understand any changes in the licensing terms or duration for PRIL and Fa, as these could impact the company's future revenue and royalty expenses.
Jyothy Labs to Hold Investor Call on June 18 for PRIL and Fa Brand License Update
Jyothy Labs Limited has scheduled a conference call for analysts and investors on Thursday, June 18, 2026, at 17:00 IST. The call is specifically dedicated to providing an update on the 'PRIL' and 'Fa' brand licenses, which are key assets in the company's portfolio. This disclosure is made in compliance with Regulation 30 of the SEBI (LODR) Regulations, 2015. The call is being coordinated by ICICI Securities and includes international toll-free access for Singapore, Hong Kong, UK, and USA.
முக்கிய அம்சங்கள்
Conference call scheduled for June 18, 2026, at 5:00 PM IST to discuss brand license updates.The discussion will focus specifically on the status and updates regarding the 'PRIL' and 'Fa' brands.Universal access numbers for the call are +91 22 6280 1144 and +91 22 7115 8045.The event is organized in coordination with ICICI Securities' equity and research heads.Information is disseminated under SEBI Listing Obligations and Disclosure Requirements.
👀 கவனிக்க வேண்டியவை
Investors should attend or review the transcript of the June 18 call to understand any changes in licensing terms, royalty structures, or duration for the PRIL and Fa brands, as these could significantly impact future margins and market share in the dishwashing and personal care segments.
Jyothy Labs to Pursue Legal Action Against Henkel Over Pril and Fa Brand License Exit
Jyothy Labs Limited has decided to initiate legal proceedings against Henkel AG & Co. KGaA following the non-renewal of license agreements for the 'Pril' and 'Fa' brands. The company aims to assert its contractual rights regarding the exit and transition mechanisms stipulated in the agreements dating back to May 31, 2011. This decision follows a Board meeting held on June 15, 2026, where the company evaluated all options to protect its interests after Henkel's initial non-renewal notice on May 9, 2026.
முக்கிய அம்சங்கள்
Jyothy Labs is pursuing legal remedies to assert contractual rights on the exit and transition mechanism for Pril and Fa brands.The dispute involves License and Technology License Agreements originally executed on May 31, 2011.The decision follows Henkel AG & Co. KGaA's communication regarding the non-renewal of these key brand licenses.The Board of Directors met on June 15, 2026, to formally approve the pursuit of legal remedies.Pril and Fa are significant brands in Jyothy Labs' portfolio, originally acquired through the Henkel India amalgamation.
👀 கவனிக்க வேண்டியவை
Investors should closely monitor the legal developments as 'Pril' is a major brand in the dishwash segment; any unfavorable outcome or abrupt transition could impact near-term revenue and market share.
Jyothy Labs Recommends ₹3.50 Final Dividend; Issues TDS Guidelines for FY 2025-26
Jyothy Labs has recommended a final dividend of ₹3.50 per equity share (350% of face value) for the financial year 2025-26. The company has issued a detailed communication to shareholders regarding the Tax Deduction at Source (TDS) process, which varies based on residency and documentation. Resident individuals can avoid TDS if their total dividend does not exceed ₹10,000, provided their PAN is updated. Shareholders must submit necessary tax exemption forms and documents by the deadline of June 25, 2026.
முக்கிய அம்சங்கள்
Recommended a final dividend of ₹3.50 per equity share of face value ₹1 (350%) for FY 2025-26.Standard TDS rate of 10% for resident shareholders with valid PAN; 20% for those without PAN or linked Aadhaar.Exemption from TDS for resident individuals if total dividend income from the company is ₹10,000 or less.Non-resident shareholders can opt for Tax Treaty rates (DTAA) by submitting TRC and Form 10F.Deadline for submission of all tax-related documents is June 25, 2026.
👀 கவனிக்க வேண்டியவை
Shareholders should verify that their PAN and bank details are correctly updated with their Depository Participant or RTA and submit relevant tax forms by June 25 to ensure correct tax withholding.
Jyothy Labs to Lose Pril and Fa Brand Licenses as Henkel Declines Renewal Beyond May 2026
Jyothy Labs has announced that its long-standing license agreements with Henkel AG & Co. KGaA for the 'Pril' and 'Fa' brands will not be renewed beyond May 31, 2026. These agreements, originally signed in May 2011, covered the manufacturing, distribution, and marketing of these brands in India. Despite negotiations, the company confirmed that no further possibility for renewal exists. Jyothy Labs is now evaluating the financial impact and the business transfer mechanism outlined in the original contract.
முக்கிய அம்சங்கள்
License for 'Pril' and 'Fa' brands to expire on May 31, 2026, ending a 15-year partnership.Henkel AG & Co. KGaA has officially decided not to renew the manufacturing and distribution rights.The 2011 agreements include pre-defined clauses for business valuation and transfer in case of discontinuation.Management is currently assessing the total financial impact of losing these key brands from their portfolio.
👀 கவனிக்க வேண்டியவை
Investors should exercise caution as Pril is a significant brand in the company's dishwash segment; monitor the valuation the company receives during the business transfer process.
Jyothy Labs Q4 FY26: Revenue Up 7.7%, Fabric Care Volumes Surge 17.8% Amid Margin Pressure
Jyothy Labs reported a 7.7% revenue growth in Q4 FY26, driven by a robust 17.8% volume growth in the Fabric Care segment. However, EBITDA margins contracted by 330 basis points to 13.5% due to rising crude-linked input costs and competitive pricing in the Dishwash category. The company successfully reduced losses in the Household Insecticides segment to INR 5 crores for the year, down from INR 25 crores. With a strong cash reserve of INR 1,000 crores and a debt-free balance sheet, the board has recommended a dividend of INR 3.5 per share.
முக்கிய அம்சங்கள்
Q4 revenue grew 7.7% YoY to INR 717 crores, while full-year FY26 revenue reached INR 2,944 crores.Fabric Care segment delivered exceptional performance with 14.4% value growth and 17.8% volume growth in Q4.EBITDA margins for Q4 declined to 13.5% from 16.8% YoY, impacted by a 400 bps drop in gross margins.Household Insecticides losses narrowed significantly from INR 25 crores to INR 5 crores for the full year.Maintained a strong liquidity position with INR 1,000 crores in cash and declared a dividend of INR 3.5 per share.
👀 கவனிக்க வேண்டியவை
Investors should monitor the impact of recent price hikes on volume growth and the company's ability to manage crude-linked inflation. The stock remains a solid play on rural recovery and premiumization in the liquid detergent space.
Jyothy Labs FY26 Net Profit Dips 10.2% to ₹333 Cr; Recommends ₹3.50 Final Dividend
Jyothy Labs reported a 3.5% year-on-year growth in annual revenue to ₹2,944.29 crore for FY26, while net profit declined by 10.2% to ₹333.19 crore. For the fourth quarter, revenue increased by 7.7% to ₹717.41 crore, but net profit fell to ₹67.52 crore from ₹77 crore in the previous year's quarter. The Board has proposed a final dividend of ₹3.50 per share, representing a 350% payout on face value. The record date for the dividend is June 29, 2026, with payment expected after the AGM on July 14, 2026.
முக்கிய அம்சங்கள்
FY26 Revenue from operations grew 3.5% YoY to ₹2,94,429 Lakhs.Full-year Net Profit declined 10.2% to ₹33,319 Lakhs from ₹37,117 Lakhs in FY25.Recommended a final dividend of ₹3.50 per equity share for the financial year 2025-26.Q4 FY26 Revenue rose 7.7% YoY to ₹71,741 Lakhs, though Q4 profit fell 12.3% YoY.Dividend record date set for June 29, 2026, with the AGM scheduled for July 14, 2026.
👀 கவனிக்க வேண்டியவை
The decline in profitability despite revenue growth suggests margin pressure from input costs; investors should monitor management's strategy for margin recovery. The steady dividend payout remains a positive for long-term income-focused investors.
Jyothy Labs FY26 Revenue Up 3.5% to ₹2,944 Cr; PAT Declines 10% Amid Margin Pressure
Jyothy Labs reported a modest 3.5% revenue growth for FY26, reaching ₹2,944 crores, while Q4 revenue grew 7.7% supported by a robust 10.8% volume growth. However, profitability was significantly impacted by rising input costs, with FY26 PAT declining 10.2% to ₹333.2 crores and EBITDA margins contracting to 15.3% from 17.6%. The company maintains a strong balance sheet with a cash balance of ₹997 crores and an efficient working capital cycle of 15 days. Management has signaled a strategy of prioritizing volume growth over margins in the near term due to persistent inflation in crude-linked derivatives.
முக்கிய அம்சங்கள்
FY26 Revenue grew 3.5% to ₹2,944 crores with 6% volume growth; Q4 volume growth was higher at 10.8%.FY26 PAT decreased by 10.2% to ₹333.2 crores, while Q4 PAT fell 12.3% to ₹67.5 crores.Operating EBITDA margin contracted to 15.3% for FY26 compared to 17.6% in the previous year due to input cost inflation.Fabric Care and Dishwash segments showed strong Q4 momentum, growing by 14.4% and 20.1% respectively.Cash and bank balances increased to ₹997 crores, providing significant liquidity for future expansions.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's ability to implement price hikes to offset input cost inflation, as margins are currently under pressure despite healthy volume growth. The strong cash position and market share gains are positive, but near-term earnings may remain volatile until raw material prices stabilize.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
